JP2023526973A5 - - Google Patents
Info
- Publication number
- JP2023526973A5 JP2023526973A5 JP2022571299A JP2022571299A JP2023526973A5 JP 2023526973 A5 JP2023526973 A5 JP 2023526973A5 JP 2022571299 A JP2022571299 A JP 2022571299A JP 2022571299 A JP2022571299 A JP 2022571299A JP 2023526973 A5 JP2023526973 A5 JP 2023526973A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid residues
- glp
- ala
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010472577.8 | 2020-05-29 | ||
| CN202010472577 | 2020-05-29 | ||
| CN202110335100 | 2021-03-29 | ||
| CN202110335100.X | 2021-03-29 | ||
| PCT/CN2021/096568 WO2021239082A1 (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526973A JP2023526973A (ja) | 2023-06-26 |
| JP2023526973A5 true JP2023526973A5 (cg-RX-API-DMAC7.html) | 2024-06-03 |
| JP7858549B2 JP7858549B2 (ja) | 2026-05-14 |
Family
ID=78745631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571299A Active JP7858549B2 (ja) | 2020-05-29 | 2021-05-28 | Glp-1とgip受容体二重アゴニスト化合物及びその応用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12653865B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4159750A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7858549B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230018395A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118754965A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021278157B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023834A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180215A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014368A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI910174B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021239082A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| CN118103391A (zh) * | 2021-11-12 | 2024-05-28 | 福建盛迪医药有限公司 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
| CN116970063A (zh) * | 2022-04-29 | 2023-10-31 | 苏州星洲生物科技有限公司 | Glp-1/gip受体共激动剂、包含其的药物组合物及其用途 |
| CN117402219B (zh) * | 2022-07-13 | 2024-07-30 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| CN115806593B (zh) * | 2022-09-23 | 2023-09-05 | 成都普康生物科技有限公司 | 一种脂肪酸链修饰的双受体激动剂及其用途 |
| CN116120425A (zh) * | 2022-12-27 | 2023-05-16 | 南京赛诺生物技术有限公司 | 一种glp-1/gip受体双重激动剂及其应用 |
| WO2024153090A1 (zh) * | 2023-01-17 | 2024-07-25 | 广东众生睿创生物科技有限公司 | 基于glp-1的三重激动剂 |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| CN116496361B (zh) * | 2023-06-25 | 2023-09-15 | 北京科翔中升医药科技有限公司 | 氘代模拟肽gip和glp-1双受体激动剂药物及用途 |
| WO2025124473A1 (zh) | 2023-12-12 | 2025-06-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物治疗代谢疾病的方法及医药用途 |
| WO2025242218A1 (zh) * | 2024-05-24 | 2025-11-27 | 上海翰森生物医药科技有限公司 | 一种多肽激动剂,其制备方法及医药用途 |
| CN119390784B (zh) * | 2024-07-11 | 2026-06-30 | 中国药科大学 | 一种双激动多肽化合物及其医药用途 |
| CN118546214B (zh) * | 2024-07-11 | 2024-12-03 | 中国药科大学 | Glp-1r受体激动多肽化合物及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP2007804B1 (en) | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1 compounds |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| CN104981186A (zh) | 2012-12-12 | 2015-10-14 | 意特发展有限公司 | 发泡器、混合器 |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| CN108271356A (zh) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| JP6581656B2 (ja) * | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | グルカゴンおよびglp−1受容体のコアゴニスト |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| CA3062194A1 (en) | 2017-06-20 | 2018-12-27 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| JP7250706B2 (ja) | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| US20210087250A1 (en) | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| AU2019309798A1 (en) | 2018-07-23 | 2021-02-11 | Eli Lilly And Company | Method of using a GIP/GLP1 co-agonist for diabetes |
| KR20250044806A (ko) | 2018-07-23 | 2025-04-01 | 일라이 릴리 앤드 캄파니 | 요법을 위한 gip/glp1 공효능제 사용 방법 |
| ES3068975T3 (en) | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| EP3856768A2 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| US20220016215A1 (en) | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| AU2020256648B2 (en) | 2019-04-11 | 2026-01-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-receptor agonist and medical use thereof |
| CN111825758B (zh) | 2019-04-19 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
| TW202120535A (zh) | 2019-11-15 | 2021-06-01 | 大陸商江蘇豪森藥業集團有限公司 | 受體雙重激動劑化合物及其醫藥組成物 |
| EP4069726A4 (en) | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | GLP2 RECEPTOR AGONISTS AND METHOD OF USE |
| IL296592A (en) | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
| JP2023534130A (ja) | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | Glp-1受容体およびgip受容体共作動薬 |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| CN116171164A (zh) | 2020-10-17 | 2023-05-26 | 太阳医药工业有限公司 | Glp-1/gip双重激动剂 |
| CA3213261A1 (en) | 2021-03-25 | 2022-09-29 | Jiandong Yuan | Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| CN115521368B (zh) | 2021-06-25 | 2024-08-23 | 江苏鸿永医药技术有限公司 | 毒蜥外泌肽-4衍生物 |
| WO2024192219A1 (en) | 2023-03-15 | 2024-09-19 | Viking Therapeutics, Inc. | Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders |
| WO2025024788A1 (en) | 2023-07-27 | 2025-01-30 | Biomedit, Llc | Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof |
-
2021
- 2021-05-28 CN CN202410666887.1A patent/CN118754965A/zh active Pending
- 2021-05-28 TW TW110119502A patent/TWI910174B/zh active
- 2021-05-28 JP JP2022571299A patent/JP7858549B2/ja active Active
- 2021-05-28 EP EP21812549.0A patent/EP4159750A4/en active Pending
- 2021-05-28 BR BR112022023834A patent/BR112022023834A2/pt unknown
- 2021-05-28 US US17/927,304 patent/US12653865B2/en active Active
- 2021-05-28 WO PCT/CN2021/096568 patent/WO2021239082A1/zh not_active Ceased
- 2021-05-28 KR KR1020227043237A patent/KR20230018395A/ko active Pending
- 2021-05-28 CN CN202410663771.2A patent/CN118530333A/zh active Pending
- 2021-05-28 CA CA3180215A patent/CA3180215A1/en active Pending
- 2021-05-28 CN CN202180004912.4A patent/CN114222755B/zh active Active
- 2021-05-28 AU AU2021278157A patent/AU2021278157B2/en active Active
- 2021-05-28 MX MX2022014368A patent/MX2022014368A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2729481B1 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| CN107531806B (zh) | 融合蛋白 | |
| KR101352225B1 (ko) | 신규한 엑센딘 변형 및 이들의 콘쥬게이트 | |
| EP2621538B1 (en) | Engineered polypeptides having enhanced duration of action | |
| JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| KR101424550B1 (ko) | 지속형 인슐린 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물 | |
| JP7858549B2 (ja) | Glp-1とgip受容体二重アゴニスト化合物及びその応用 | |
| KR20220061057A (ko) | 지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물 | |
| US9879063B2 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| JP2018135346A5 (cg-RX-API-DMAC7.html) | ||
| JP2023545684A5 (cg-RX-API-DMAC7.html) | ||
| JP2013517307A5 (cg-RX-API-DMAC7.html) | ||
| JP2012529463A (ja) | 2型糖尿病を治療するための、glp−1とfgf21との組合せ | |
| JP2006348038A (ja) | Glp−1誘導体 | |
| JP2024546026A5 (cg-RX-API-DMAC7.html) | ||
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| JP2023500895A5 (cg-RX-API-DMAC7.html) | ||
| JP2023144098A (ja) | ポリペプチドを含む医薬組成物 | |
| CN102781458A (zh) | 多肽缀合物 | |
| RU2025118079A (ru) | Аналог инкретина и его применение | |
| CA2950266C (en) | Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate | |
| RU2021128100A (ru) | Мультирецепторный агонист и его медицинское применение | |
| TH2001006159A (th) | คอนจูเกตเพปไทด์ไทโรซีนไทโรซีนแบบไซคลิกที่ถูกคู่ควบด้วยเพปไทด์หลอมรวมชนิดเพปไทด์ที่คล้ายกลูคากอน 1 (glp-1) และการใช้สารนั้น | |
| HK1196624B (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| HK1188710B (en) | Engineered polypeptides having enhanced duration of action |